Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bill Proposes Offering Exclusivity For Novel Drug Co-Development

Executive Summary

Bill proposes six months’ extra marketing exclusivity to spur development of combinations of investigational drugs for serious diseases. Setting aside prospects for passage in an election season, the question is whether that will be enough to get pharma to buy into a risky development space and pioneer a new business model.

You may also be interested in...



FDA Antibiotic Task Force Developing Standards To Help Products GAIN Traction

Task force model emerging as agency’s standard approach to implementing statutory directives to enhance product development.

View From ICAAC: How Higher Prices Can Help Save Antibiotic R&D

At the annual anti-infectives meeting, experts consider revamping the business model to spur development of novel antibiotics, with cooperation of regulators in Europe and U.S.

Bristol/Roche Finally Start Combination Melanoma Trial

The drug makers, potential competitors, will study Bristol's CTLA-4 inhibitor Yervoy in combination with Roche's investigational BRAF inhibitor vemurafenib in metastatic melanoma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel